Search

Displaying results 2741 - 2750 of 10000 in total
  1. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [L48781] In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.

  2. Drug

    Terlipressin

    go.drugbank.com/drugs/DB02638
    ApprovedInvestigational

    Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. … [A252672] The drug was first approved by the FDA in September 2022.[L43217]

    Categories: Vasopressin Receptor AgonistProducts: ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, GLYPRESSIN 1 MG IV ENJEKSIYONLUK TOZ IÇEREN FLAKON VE ÇÖZÜCÜ AMPUL, 1 ADET
  3. Drug

    Coccidioides immitis spherule

    go.drugbank.com/drugs/DB11294
    Approved

    Coccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.

  4. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. … Tafasatimab is designed to bind to and block the activity of the CD19 surface antigen, which ultimately results in the lysis of B-cells (both healthy and malignant).

  5. Indication

    XLH

    go.drugbank.com/conditions/DBCOND0125908
    Drugs: Burosumab
    Synonyms: Calcitriol receptor defect
  6. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW. … The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22.

  7. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    [L7489] In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.

    Categories: Programmed Death Receptor-1 Blocking Antibody, Programmed Death Receptor-1-directed Antibody Interactions
  8. Drug

    Asunaprevir

    go.drugbank.com/drugs/DB11586
    ApprovedWithdrawn

    The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113] … It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.

  9. Drug

    Fludarabine

    go.drugbank.com/drugs/DB01073
    ApprovedInvestigational

    Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

  10. Drug

    Erythrityl tetranitrate

    go.drugbank.com/drugs/DB01613
    ApprovedWithdrawn

    A vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)

    Synonyms: Tetranitrato de eritritilo